It has been shown that VEGF can predict disease recurrence in patients with stage II colon cancer and can be used to identify patients at high risk of recurrence who may benefit from adjuvant therapy.[27] Liu et al[28] performed risk scores by detecting protein kinase B, VEGF, and NIN1/RPN12 binding protein 1 homolog in resected non–small-cell lung cancer and found that the postoperative survival rate of resected non–small-cell lung cancer patients could be predicted based on the risk scores expressed by protein kinase B, VEGF, and NIN1/RPN12 binding protein 1 homolog. This evidence concerns the gene VEGFA and colonic neoplasm.